Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.24 | N/A | -24.37% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.24 | N/A | -24.37% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, reflecting on the difficulties encountered. They did not offer specific insights into future performance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged the challenges faced during the quarter.
Veracyte's earnings report indicates a challenging quarter, with a notable EPS miss. The stock reacted negatively, declining by 1.85%, likely due to the lack of revenue details and future guidance. Investors may be concerned about the company's performance and outlook moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RB GLOBAL INC
Feb 26, 2018